Home Newsfeeds Rosenblatt Reiterates Neutral on Luminar Technologies, Maintains $8 Price Target

Rosenblatt Reiterates Neutral on Luminar Technologies, Maintains $8 Price Target

Rosenblatt analyst Kevin Cassidy reiterates Luminar Technologies (NASDAQ:LAZR) with a Neutral and maintains $8 price target.

byBenzinga Newsdesk

March 1, 2023

1 minute read

Rosenblatt analyst Kevin Cassidy reiterates Luminar Technologies (NASDAQ:LAZR) with a Neutral and maintains $8 price target.

Abercrombie & Fitch’s Q2 Highlights: Earnings Miss, Inflation Hit Hollister Performance, Dismal Outlook & More

By Shivani Kumaresan

August 25, 12:50 PM

Abercrombie & Fitch Co (NYSE:ANF) reported a second-quarter FY22 sales decline of 7% year-on-year to $805.09 million, missing the consensus of…

ANF

European Central Bank Raises The Interest Rate By 75 Basis Points As Expected

By Anusuya Lahiri

September 8, 8:31 AM

ECB has raised the interest rate by 75 bps to 1.25%, in line with the expectations.

FLEE

FSD Pharma Announces Distribution Date As November 29, 2023 For Distribution Of Celly Shares Pursuant To Plan Of Arrangement

By Benzinga Newsdesk

November 17, 9:05 AM

FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that,

CSE:HUGE

Morgan Stanley Maintains Equal-Weight on Cleveland-Cliffs, Lowers Price Target to $14.5

By Benzinga Newsdesk

July 25, 8:21 AM

Morgan Stanley analyst Carlos De Alba maintains Cleveland-Cliffs (NYSE:CLF) with a Equal-Weight and lowers the price target from $16 to $14.5.

CLF

Rosenblatt Reiterates Neutral on Luminar Technologies, Maintains $8 Price Target

Related Posts

Abercrombie & Fitch’s Q2 Highlights: Earnings Miss, Inflation Hit Hollister Performance, Dismal Outlook & More

European Central Bank Raises The Interest Rate By 75 Basis Points As Expected

FSD Pharma Announces Distribution Date As November 29, 2023 For Distribution Of Celly Shares Pursuant To Plan Of Arrangement

Morgan Stanley Maintains Equal-Weight on Cleveland-Cliffs, Lowers Price Target to $14.5